Multiple pathogen detection using nanoplasmonic sensing by Filippini, Chiara
ALMA MATER STUDIORUM- UNIVERSITA’ DI BOLOGNA 
CAMPUS DI CESENA  
SCUOLA DI INGEGNERIA E ARCHITETTURA 
 
CORSO DI LAUREA MAGISTRALE IN INGEGNERIA BIOMEDICA 
 
 
 
MULTIPLE PATHOGEN DETECTION USING NANOPLASMONIC 
SENSING 
 
Tesi in 
Biochimica 
 
Relatore:                                                                             Presentata da: 
Emanuele Domenico Giordano                                       Chiara Filippini 
 
 
 
                                             Sessione: I° sessione 
                                             Anno Accademico: 2013/2014 
 
ABSTRACT 
 
Opportunistic diseases caused by Human Immunodeficiency Virus (HIV) and 
Hepatitis B Virus (HBV) is an omnipresent global challenge. In order to manage 
these epidemics, we need to have low cost and easily deployable platforms at the 
point-of-care in high congestions regions like airports and public transit systems. 
In this dissertation we present our findings in using Localized Surface Plasmon 
Resonance (LSPR)-based detection of pathogens and other clinically relevant 
applications using microfluidic platforms at the point-of-care setting in resource 
constrained environment. The work presented here adopts the novel technique of 
LSPR to multiplex a lab-on-a-chip device capable of quantitatively detecting 
various types of intact viruses and its various subtypes, based on the principle of a 
change in wavelength occurring when metal nano-particle surface is modified with 
a specific surface chemistry allowing the binding of a desired pathogen to a 
specific antibody. We demonstrate the ability to detect and quantify subtype A, B, 
C, D, E, G and panel HIV with a specificity of down to 100 copies/mL using both 
whole blood sample and HIV-patient blood sample discarded from clinics. These 
results were compared against the gold standard Reverse Transcriptase 
Polymerase Chain Reaction (RT-qPCR). This microfluidic device has a total 
evaluation time for the assays of about 70 minutes, where 60 minutes is needed for 
the capture and 10 minutes for data acquisition and processing. This LOC platform 
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eliminates the need for any sample preparation before processing. This platform is 
highly multiplexable as the same surface chemistry can be adapted to capture and 
detect several other pathogens like dengue virus, E. coli, M. Tuberculosis, etc.  
Keywords: HIV * Point-of-care * LSPR * lab-on-a-chip * RT-qPCR * E. coli * 
HBV  
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Chapter 1 
Review of point-of-care diagnostic technologies 
1.1 Introduction 
In the past two decades, the role-played by nanotechnology and Micro-technology has 
been crucial for the growth of the research in fields like biomedical engineering and 
chemical engineering. These technologies are now emerging as important tools that can 
be used even in resource constrained settings and in many developing countries that lack 
the basic infrastructure to support large scale clinical diagnostic laboratories. Instead we 
are now moving into an era where we are bringing the entire lab at the point-of-care so 
that patients who are not able to access such expensive diagnostic tool can have early 
stage detection of diseases caused by pathogens. The work done by Won G. Lee et al. [1] 
at the Bio-Acoustics MEMS in Medicine Laboratory and Center for Biomedical 
Engineering at the Brigham and Women’s Hospital, brings to light some very important 
developments in the field of microfluidics that can aid in the detection of diseases in 
resource constrained setting.  
 
Figure 1: The use of finger prick amount of blood to perform rapid test at the POC. Ref [1] 
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These micro scale platforms offer immense possibilities like manipulation of fluids in 
channels of sub-millimeter scale, which is a very important step in many assay processing 
for pathogen detection. Reports published by the United States Center for Disease 
Control states that nearly 94.8% deaths in many developing countries is primarily due to 
the lack of timely diagnosis or affordable healthcare.  
In response to the increasing need for early detection of pathogens, the World Health 
Organization has set up the ASSURED protocol, which calls for new technologies to be: 
“Affordable, Specific, Sensitive, User-friendly, Robust, Equipment free and Delivery to 
the needy” [1]. Based on these guidelines many researchers are now developing point-of-
care devices that help in reducing costs and improving detection capabilities of microchip 
[12]. 
One of the important features of microfluidics is the fabrication that has been adapted 
from VLSI technology and evolved to suit plastic based fabrication. The need for high 
capillarity surface calls for materials engineering and the use of materials like PMMA, 
PDMS, DSA, FLASH, etc. all of which respond well to lithography and laser cutting 
based design and fabrication. 
 
Figure 2: Materials like PMMA, PDMS and Glass chips. Ref.[2] 
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1.2 Categories of Research development  
 
Broadly we can categorize the various developments in the field of microfluidics as 
follows, each of which has been described in the following section.  
1. Microchip imaging and detection: Imaging and detection based on microfluidic chips 
can be achieved using several methods. The most important of which are: Optical 
microscopy, opto-fluidics (the fusion of imaging and microfluidics), and detection 
using methods like SPR, LSPR, absorbance, fluorescence, interferometer, or 
luminescence. Other methods include the use of Portable CCD, and more recent 
technologies like mobile phone based imaging and microscopy [12]. 
 
Figure 2a: Various categories of development in Micro/Nanotechnology 
 
2. Flow cytometer microfluidics: The most important feature of microfluidic flow 
cytometer are: label-free detection, lens less imaging, simple design of channels, 
sheath-free focusing [9]. 
3. Immunoassay based chips: Recent developments in the area of immunoassay include 
a miniature ELISA chips to perform Rapid Diagnostic Test (RDT), other devices 
include those based on lateral flow and diffusion. Microchips with diffusion based 
immunoassay for detecting quantities of small molecules have also been developed. 
4. Nanosensors: There are many new nano-devices that are capable of detecting 
extremely low amounts of nanoparticles like DNA and viruses. Some notable devices 
Microchip 
detection 
and imaging 
Microfludic 
flow 
cytometer 
Nanosensors 
Immunoassay 
fbased 
Microchips 
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are: nanotubes and nanowires based on CNT, AFM based detection, glass- based 
ViriChip, etc. [9,12]. 
The integration of all these types of sensors into one global healthcare network is the 
general direction of research in health science and information technology. Achieving 
such level of comprehensive network integration [9] would mean that virtually patient 
and healthcare provider can be separated geographically and yet interact with concrete 
clinical data at the patient end. 
 
 
Figure 3: Flow chart of integrating POC with wireless networks. Ref. [1] 
 
The CCD works on the principle, where the shadow of the image of the cells falls on the 
photoactive surface of the CCD [9,12] and this change in intensity produces electrical 
charge that is imaged and tracked. In order to illustrate the devices like CCD and DAPI 
staining we illustrate the following: 
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Figure 4 a. CCD Imaging of chips with flow of CD 4 T lymphocyte cells, 4b. Phase contrast, 
DAPI imaging, CD4+ stain, CD3+ stain cells.  Ref.[1] 
 
The rapid growth of these micro technologies makes it possible to detect diseases like 
Malaria using the lateral flow based immunoassay sensors. Lateral flow based Rapid 
Detection Tests (RDT) are very commonly used for Malaria diagnosis. A few decades 
microscopy of the blood sample was considered the “gold-standard” of detection. These 
RDT based chips are able to sense the proteins in the blood of Malaria patients. The chip 
if tested positive would display a series of lines to show the binding of antigen with 
antibody at the lines. It must be noted that such chips must have channels that are able to 
accommodate the cells found in the blood, ranging from RBC to WBC [9]. This device 
has been illustrated below in Figure 5. 
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Figure 5: RDT chip for the detection of Malaria. Ref [9] 
 
It has also been estimated that nearly a third of the world’s population has been affected 
with Latent form of Tuberculosis infection or have actually contracted the disease in its 
active form. In order to detect TB at an early stage T. Spot test is done along with the 
Tuberculin Skin Test (TST). However, those who are asymptomatic may not be 
diagnosed at all until they actually develop the TB infection [9,12]. The study done by H. 
Lee et al. on the use of magnetic nanoparticles based NMR method of detecting TB has 
shown promising results for use in resource constrained  setting. When the magnetic NP 
(MNP) are in monodispense state of about 38 nm in size, the relaxation time of the NMR 
is linearly decreasing with T= 40 ms. However when the MNP form clusters and size 
increases to 300 nm, the magnetic relaxation time fall faster at T= 14 ms. An integrated 
micro RF coil on a chip can be used to excite the system and produce the required 
magnetic excitation. 
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Figure 6: TB detection chip using NMR a. Assay containing MNP, b. Device  schematic, c. 
RF micro coil to excite the MNP in the assay, d. The microfluidic network channel, e. The 
signal processing circuit. Ref [9] 
 
We have also seen the increasing trend in Cell Phone based microscopy and imaging that 
has helped in connecting patients from remote locations with the primary care provider. 
Portable CCD are also an effective alternative to provide reliable results in case of blood 
samples with border limit amounts of biomarkers. In conclusion to Chapter 1, we see the 
increasing trend in the use of POC device at resource-constrained settings for monitoring 
the spread of diseases and pathogens. From HIV/AIDS, to Tuberculosis on a chip and 
Malaria detection using RDT immunoassay based chips, LOC devices are being adapted 
to meet the pathological needs of various disease detection gold standard protocols [12]. 
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Chapter 2 
Physics of Localized Surface Plasmon Resonance 
2.1 Introduction 
Surface Plasmon resonance (SPR) and localized surface plasmon resonance (LSPR) are 
both powerful tools for label-free bio-sensing in biochemistry due to their high sensitivity 
to the refractive index change caused by their interactions with molecules such as DNA 
or proteins, etc. SPR is known as a phenomenon excited when the frequency of 
evanescent electromagnetic wave propagating at the metal-dielectric interface is resonant 
with the oscillation of the surface conduction electrons in metal [40]. LSPR often refers 
to metallic nanoparticles as it occurs when the frequency of incident photon is resonant 
with the collective oscillation of conduction electrons in metallic nanoparticles. Bio-
sensing has traditionally employed spectroscopic techniques that measure biological 
interactions in solution; however, performing assays on a surface has certain advantages: 
surface assays require less sample than solution assays; they permit real-time 
measurements; they are readily amenable to high throughput sensing since probe 
functionalized surfaces are easily washed and regenerated enabling sequential 
measurements; and a single surface can be functionalized with an assortment of probes 
for multiplexed simultaneous sensing [41]. SPR and LSPR technologies are based on the 
wave propagation or electromagnetic field enhancement phenomena near metal surfaces 
or nanoparticles. The propagating surface plasmon polaritons excited on plane metal 
surfaces are utilized in SPR sensors. LSPR relies on the field enhancement and 
confinement in close proximity to nanoparticles. The localized field oscillations around 
nanoparticles motivate the name “localized” in LSPR. The plasmon modes extend up to a 
few tens of nanometers in LSPR sensors, allowing sensitive sub-wavelength biosensors. 
SPR biosensors interrogate the resonance angle changes to detect and quantify bioagents. 
LSPR measurements are in the form of absorbance or spectral shift data obtained from 
extinction curves. In general, sensitivities of these resonance or extinction shifts to 
refractive index changes are used to quantify figure of merit parameters for SPR and 
LSPR sensors[42]. 
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2.2  Physics principles 
 
 
Figure 7: Plane-wave, refracting, and reflecting light at a metal−dielectric interface. n2 and 
n1 are the refractive indices of the metal and the dielectric mediums. E is the electric field 
vector, B is the magnetic field vector, and k is the wavevector. The indices i, r, and t are for 
incident, reflecting and refracting light. The magnetic field is perpendicular to the plane of 
incidence, representing transverse magnetic light. 
 
To analyze the propagation of surface plasmons along a metal−dielectric boundary, we 
consider the reflection and refraction of light between two infinite media. A linearly 
polarized, monochromatic light propagates from the dielectric medium toward the 
metallic surface, as shown in Figure 7 [41]. To explain the SPR theory, transverse 
magnetic (TM) polarized incident light is used. TM polarization indicates that the 
magnetic field vector is in the plane of the metal−dielectric interface. There is no loss of 
generality in using TM polarization, since transverse electric modes cannot excite surface 
plasmons. Solving Maxwell’s equations for the p-polarized light for the wavevector 
components, one can find the surface plasmon dispersion relation: 
    
 
 
√
    
     
                 
 
 
√
  
 
     
 
Here, the medium is indicated by the first subscript (i.e., i = 1 for dielectric medium and 
i= 2 for metal medium), the axis is indicated by the second subscript, k is the wavevector, 
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ω is the angular frequency of the light, c is the speed of light in vacuum,   and    are the 
refractive indices for the metal and the dielectric media, respectively,    =  
 ,    =  
 , and 
   and     are the dielectric constants of the media. From the boundary conditions it also 
follows that k1z = k2z. Since medium 2 is a metal, the dielectric constant    and     are 
complex-valued quantities, resulting in the exponential decay of the plasmon field in both 
media, in the direction of the x-axis. This decay results in a surface wave, confined to the 
metal−dielectric interface [40]. Physically, the incident photons couple to the free 
electrons on the interface, resulting in a propagating surface charge-density oscillation. 
The     component of the wavevector defines the wavelength of the resonance oscillation 
and also the extent of the plasmon wave over the interface before absorption by the metal. 
For long-range and bound plasmon waves in an ideal, lossless medium, a real-valued 
   and an imaginary-valued    are required, i.e. ε1*ε2 < 0 and ε1 + ε2 < 0, ignoring the 
imaginary parts of the dielectric constants. At optical wavelengths these two conditions 
are satisfied for gold and silver, which are commonly used metals in SPR experiments. 
Field components of the plasmon modes take their highest values at the interface and 
exponentially decay into the metal and dielectric media. The penetration depth of the 
fields into both mediums are given by 1/Im(   ) and 1/Im (   ), where Im is the 
imaginary part. The penetration depth in the dielectric media is on the order of half the 
wavelength of the incident light. For instance, for a gold−water interface and λ = 700 nm, 
the penetration depth in water can be calculated to be around 238 nm. When there is a 
local change in the dielectric constant over the metal layer, which is caused by a 
molecular binding event, the surface plasmon mode energy will be changed [2]. The SPR 
biosensors rely on this property of the resonance. Since the total energy of the system is 
conserved, the change in the plasmon mode’s energy will leave a signature on the 
reflected or transmitted light. In SPR biosensor applications, light is monitored and 
analyzed to extract binding and kinetic information. This analysis is related to which 
method is utilized to couple the light to plasmon modes.  
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2.2.1 Physical absorption  
Physical adsorption technique utilizes the surface characteristics and surface charge to 
attach and immobilize biorecognition elements onto the surface and relies on nonspecific 
physical interactions between the recognition element and the support material. In 
contrast to chemical binding techniques, this method also holds a key advantage since it 
does not require any reagent to activate chemical groups on the surface, and thus, this 
technique is easy to perform, inexpensive, and reduces structural damage in 
biorecognition elements. The physical adsorption method particularly utilizes hydrogen 
bonding and van der Waals forces. These weak interactions also allow the biorecognition 
elements to easily detach from the surface, and thus, the biosensing surface can be used 
multiple times [30]. However, nonspecific physical interactions are closely affected by 
environmental changes, including temperature, ionic content, and pH. On the other hand, 
this technique causes nonspecific binding of other molecules and substances, resulting in 
a significant decrease in surface coverage of the recognition elements and sensor 
specificity. The support materials can be modified to generate surface charge and reactive 
groups using oxidizing techniques such as oxygen plasma treatment. On plasma-treated 
slides, the binding amount of oligonucleotide−protein conjugates significantly increased 
compared to untreated slides. Another interesting observation in this study was that 
plasma treatment amplified the surface area and formed nanoroughened structures that 
could facilitate detection of a low amount of target analyte and improve the analytical 
performance of the biosensing surface in microarray applications. Although oxygen 
plasma treatment is a simple and effective method for many surfaces, it often causes 
significant damage on the biosensing support surface [31]. This major obstacle leads to 
permanent surface disruptions, which interfere with the sensor surface structure and 
reduce sensitivity. On the other hand, the surface characteristics (e.g., hydrophobicity and 
polarity) and the functional groups of biomolecules determine the molecular interactions 
for biomolecule immobilization. Although, in some cases, the orientation of the 
recognition element is not critical to capture the target analyte, these molecular changes 
on the surface can affect biomolecular activity (e.g., denaturation of proteins) and 
orientation of proteins and antibodies due to the restrictions in their conformational 
flexibility.  
 15 
2.2.2 Principle of detection:  
The entire principle of detection for the pathogens and other biological entities like live 
cells from the human body or drugs that are being multiplexed on the microfluidic 
platform rely on the physics of Localized Surface Plasmon Resonance. As depicted in 
Figure 8 below, we can see than a single frequency (monotone) light is shone on the 
sample at a particular angle of incidence. A prism placed in the near field split the 
monotone light such that multiple rays of light shine at various angles of incidence. When 
the electromagnetic wave hit the surface containing some type of surface chemistry over 
the Gold nanoparticle layer, the metal NP absorb some amount of energy and produce 
Surface Plasmon Polaritons (SPP). These waves propagate [17] along the surface and are 
called Plasmon waves. The remaining incident light is reflected off the surface or 
transmitted (depending on the optical set up) with a frequency spectrum component that 
is different from that of the incident radiation. 
 
Figure 8: Physics of Surface Plasmon Resonance. Ref [17] 
 
From the spectrum band we can detect the range of frequencies that were absorbed by the 
microfluidic platform by virtue of the surface modified layers over the metal NP. In order 
to illustrate the effect of surface modification on the spectrum of absorbance, we show in 
Figure 8a the surface containing conjugated antigen and antibody. 
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Figure 8a: Model Spectrum and effect of surface modification with Antigen-antibody 
binding effect  
From the above graph we can see that before adding any receptor that frequency 
spectrum has a specific band of absorbance. However when there is also a receptor along 
with the antigen antibody, the spectrum is different from the previous one obtained. As 
shown in Figure 8b the resonance plot has two different regions. In the first region the 
association and dissociation effect of the antibody [1,2,3] is shown and the second curve 
shows the effect of receptor binding on the spectrum. 
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Figure 8b: The change in spectrum for surface modification with Antigen-antibody and 
receptor binding 
 
2.3 Characteristics of LSPR and SPR. 
The terminology “resonance” is used to highlight the match in frequency between the 
incident electromagnetic radiation and the frequency of the generated surface plasmon 
electrons waves (these electrons vibrate to and fro by virtue of the nuclear attraction in a 
polarized atom). This technique of LSPR [1,3,17] is very sensitive to any surface 
modification as this surface forms the boundary interface where SPP is generated. The 
materials dielectric constant at the interface changes in response to any addition 
biological species or chemical molecules. The addition of such molecules gives rise to a 
complex electrical permittivity to the metal NP, which causes absorption of the incident 
radiation. The SPP produced have higher amplitudes of oscillation in the near field 
resonant condition. Another important characteristic of the SPP waves is that, they have 
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maximum intensity in the metal NP and decay rapidly outside the NP-dielectric interface. 
In order to generate SPP waves, the incoming electromagnetic radiation needs to be p-
polarized, which means the waves in parallel polarized to the incident plane. If the 
incoming radiation has a polarization perpendicular to the surface, such a wave would be 
incapable to generating SPP. The generated SPP obey the below relation, known as the 
dispersion equation: 
 ( )   
 
 
 √
        
          
             
where,    is the electrical permittivity and    is the magnetic permeability of the 
interface. The Varioskan  scanning machine uses a Kretschmann configuration [17] of 
generating SPP, in which the prism is placed in close proximity to the surface. This 
configuration is also one of the most commonly used in commercial devices, as opposed 
to the Otto Configuration of prism arrangement, which relies on the evanescent radiation 
to excite SPP. 
The other important advantage of LSPR based microfluidic detection platform is the label 
free nature of detection. In conventional methods like Enzyme Linked Immunosorbent 
Assay (ELISA) or Lateral Flow Assay (LFA), the detection is dependent on a secondary 
label and multiple processing steps involving rinsing [1,3].  
     
Figure 9: Relation between LSPR Peak shift and Number of biomolecules and Size of 
nanoparticle. Source [1,3]. 
 19 
 
From Figure 9 we can see the relationship between the amount of peak shift in LSPR as a 
function of the number of biomolecules captured on a surface of gold nanoparticles and 
the size of the Au NP. In order to better understand Figure 9, we plot the individual 
graphs as below for 3 different radii of the Au NP. 
 
Figure 9a: Peak shift as a function of layer thickness for Au NP of 5nm, 20nm, 50nm 
 
2.3.1 Mie Theory of Localized Surface Plasmon Resonance 
LSPR relies on the change in refractive index (R.I.) of the media as a means of sensing 
bio-particles or pathogens. The key benefits of LSPR also arise from the fact that metal 
NP like that of gold and silver display a very good UV-Visible absorption spectrum with 
distinct bands which is not observable in bulk Au or bulk Ag. This method results in 
wavelength specific absorption of high molar extinction coefficient, typically 3 x 10
11 
M
-
1
cm
-1 
and the Rayleigh scattering has efficiency about 1000,000 fluorophors [17]. The 
best available analytical model that describes this behavior of nanoparticle is the Mie 
Theory of the estimation of extinction or (absorbance + scattering).  
 ( )   
      
   
   
    (  )
[
  
(       )     
 ] 
In the above analytic model,  ( ) represents the sum of absorbance and scattering for 
any wavelength lambda, known as extinction, NA denotes the surface area occupied by 
the Metal-NP of radius ‘a’,  m  is the electrical permittivity of the surrounding media, 
which is wavelength independent and real valued (instead of complex valued),  i and  r 
represent the imaginary and real parts of permittivity of the Metal-NP and   denotes the 
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spatial resolution, in our case two assuming two Metal NP would be coalesce or 
aggregate.  The above model best represents the various parameters on which the LSPR 
spectrum would depend on.  
 2.3.2 LSPR Example using Streptavidin 
Streptavidin and biotin interaction is perhaps one of the most well studied and 
documented pair to understand LSPR. From the graph below obtained from one such 
study, we see that the peak occurs at about 500- 520 nm, which is characteristic for the 
peak of Ag NP. The plot denotes the spectrum before adding 9nM of Streptavidin and 
after the addition of 9nM of streptavidin [1,2,3]. The plot 1 has a peak at 507 nm when it 
has biotinylated silver nanoparticle whereas peak 2 is the same surface after incubating 
the sample with streptavidin for 3 hours.  
 
 
Figure 10: LSPR Plot for biotinylated silver and streptavidin interaction. 
 
Figure 11: LSPR plot for silver NP with streptavidin and the binding response 
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In order to illustrate the studies done on streptavidin, we can see from the plot on the left, 
that the peak is 606 nm before adding SA and 636 nm after adding SA, whereas the curve 
on the right denotes the SA binding at different concentrations ranging from 10
-15
 M to 
10
-7
 M. It is interesting to note that the response of both these platforms can be described 
by the equation: 
          (     
( 
  
  
)
 ) 
With       is the wavelength shift response, m is the sensitivity to refractive index, 
   denotes the change in the R.I. that is created due to the substance adsorbed with 
thickness d, and ld is the evanescent decay length [1,2,3]. 
 
2.3.3 SPR and LSPR 
 
Table 1: Comparison between SPR and LSPR Ref. [18,19,20,21] 
Feature SPR LSPR 
Label Free detection Yes Yes 
Distance dependence 1000 nm 30nm (size tuneable) 
Modes Angle Shift, Wavelength Shift, 
Imaging 
Extinction, Scattering, 
Imaging,  
Chemical identification SPR Raman Scattering LSPR Raman Scattering 
Small molecule sensitivity Good Better 
Refractive Index Sensitivity 2E6 nm/RIU 2E2 nm/RIU 
Multiplex capability Yes Yes 
Field Portability No Yes 
 
Comparison between SPR and LSPR is depicted in the above table. As compared, we see 
that both SPR and LSPR offer label free detection of biomolecules and pathogens, 
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however SPR has a supreme distance dependence on detection with up to 1000 nm, 
however LSPR needs the detection distance in the order of 30 nm. Example of surface 
chemistry done for anti-casein antibody is illustrated in the diagram below. We can see 
that the deposition of 5nm Chromium and 30 nm of gold layer followed by DDA 
incubation via a self-assembly in a mono-layer [3]. 
 
 
Figure 11a: Surface chemistry using DDA, APTES and mono-layers of Silica NP 
Figure 11b: Surface chemistry for Protein A based biosensor using gold NP 
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The LSPR data obtained from the above set up is shown below. The Atomic Force 
Microscopy image for the surface shows the surface smoothness when the gold NPs are 
incubated. The plot on the left however, shows the absorbance peak for gold NP at 550 
nm [1,2]. 
  
Figure 12: LSPR plot for anti-casein antibody over gold NP and AFM imaging 
 
 
 
2.3.4 Surface chemistry 
 
As a preliminary step, after have been functionalized our platform surface with gold 
nanoparticle,  we tested different parameter that characterize the surface chemistry to 
choose the better combination for starting our experiments.  
The aim of this first step is to analyze the sensor response to different buffers parameter 
such as:  
pH, temperature, durability 
We start from the comparison between different pH. For this purpose, we prepared Borax 
NaOH pH=10, PBS pH= 7.4, MES pH= 5.  Incubating for: 
1hour, 1 day, 2 days, 3 days, 7 days, 14 days, 21 days. 
Phosphate buffered saline (abbreviated PBS) is a buffer solution commonly used in 
biological research. It is a water-based salt solution containing sodium phosphate, sodium 
chloride and, in some formulations, potassium chloride and potassium phosphate. The 
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osmolarity and ion concentrations of the solutions match those of the human body 
(isotonic). PBS has many uses because it is isotonic and non-toxic to most cells. 
 
 
pH- durability experiment 
 
 
 
Figure 13 : wavelength shift of 3 different buffer, PBS (pH=7), MES (pH=5), Borax NaOh (pH= 10) after being 
incubating for 1, 5, 7, 14 days. 
 
 
From this results we can notice that all the buffers shows a wavelength shift and they can 
be used from one day till 14 day with no much efficiency difference. So we chose PBS 
buffer as it is the cheaper and the most common in the literature. 
 
Temperature experiment 
 
 
 
Figure 13a: wavelength shift of PBS buffer in 3 different temperature condition ( 4°C, 25°C, 37°C) 
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As the second step we tested different temperature, such as: 4°C, 25°C, 37°C and we 
used room temperature as a control.  We can clearly see that PBS have a very small 
wavelength shift, so that we choose to use the buffer at 37°C to have a more detectable 
peak. 
 
 
 
 
  
 26 
Chapter 3 
Detection of Escherichia coli using Lab-on-a-chip platform 
Disease causing agents, like E. coli, dengue virus, HIV, HBV, etc. are a grave cause of 
concern in today’s time of growing healthcare costs. Health ailments like that arising 
from contaminated food sources, injuries that attract infections, such sepsis or growth of 
other pathogens. It has become very important and vital to reduce associated healthcare 
cost by detecting these pathogens and other disease causing agents at early stage in 
resource constrained settings. The present state of the art techniques that involve 
Polymerase chain reaction (PCR and its variants like RT-qPCR, qPCR, etc.) or agar plate 
culture for processing samples has the main drawback of high cost, large processing time, 
technical expertise and lack of deploy ability at the point-of-care. This challenge is still 
being address by the biomedical research community and much work can still be done to 
overcome such challenges. In this chapter we describe a low cost POC method of 
detecting E. coli in clinically relevant conditions [9] like Phosphate buffered saline, 
whole milk, dietary spinach, and whole blood from patients. We use a immunoassay 
based microfluidic chip to capture these pathogens and then enumerate them with high 
accuracy and reliability. The results indicate that there is close to 70% capture efficiency 
for the bacteria in PBS solution when using LPS binding protein. It must also be noted 
that PBS, whole blood, and milk samples had a very detection cut off close to 50 Colony 
Forming Unit (CFU) per mL, however, with spinacia oleracea (common spinach) the 
limit of detection was as high as 500 Colony Forming Unit (CFU) per mL. The work 
done by researchers at the Bio-Acoustics MEMS in Medicine Laboratory at the 
Massachusetts Institute of Technology and Harvard Medical School is focused on using 
such novel technologies for developing POC device for detecting multiple pathogens 
using MEMS and microfluidic platforms. According to the United States Center for 
Disease Control (CDC), sepsis is one of the most lethal health condition that has a 
mortality rate as high as 29% to 49.78% as of 2013. Sepsis is categorized as a whole 
body condition in response to any infection, also known as “Systemic Inflammatory 
Response Syndrome” a.k.a. SIRS in the medical community. Organ failure, high lactose 
content in blood, increased amount of bacteria in blood, etc. are just few possible side 
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effects of a severe inflammatory response. A declining immune system, pyrexia, rashes, 
low blood pressure, organ failure, are all indication that sepsis is the diagnosis. Most 
patients who are diagnosed with sepsis are given broad spectrum anti-biotic in response 
to the bacterial infection. However, a prolonged usage of this medication, causes the 
bacteria to develop immune response that would make them resistant to the BSAB. There 
have been many developments in response to developing efficient drugs, early detection 
using appropriate biomarkers, etc. for sepsis, however, the number of people who are 
dying of sepsis each year has been increasing if not stabilizing at a constant value. The 
CDC predicts that roughly 75.9 million people are affected by food borne pathogens and 
vectors, leading to more than 300,000 emergency hospitalization cases and close to 4780 
deaths every year. Other organs within the United States, like the DOA have reported that 
the annual loss to the US government from pathogens from food sources, like E.coli is 
approximately $ 6.778 billion. Almost two years ago, in 2011 Shiga toxins belonging to 
Stx1 and 2 from the lambdoid prophages, caused by E. coli were a cause of global 
concern. It is believed that these Shiga toxins block the protein synthesis pathways in the 
host cell or the target. They enter the host through a macropinosome and once inside the 
host, they behave like N-Glycosidase protein where they break a specific adenine bond in 
the mRNA, thus stopping protein production [9]. 
 
Figure 14: The chemical structure (Ribbon diagram) of the Stx1 and Stx2 toxins. Ref [18] 
It has been reported that Sepsis is the 10
th
 leading cause of mortality resulting in about 
25,000 deaths over a study period of seven years in 48 hospitals in the United States. 
These data show that the early stage detection of E.coli, the main causative agent of 
sepsis, is very important.  
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The present technique of Agar plate culture is the most reliable method and often coined 
as the gold standard for detecting pathogens like E.coli from various food samples. 
 
 
Figure 15: Agar plate culture sample in RBC for pathogen detection. Ref [18] 
In order to compare how traditional methods like agar plate culture using MacConey agar 
plate versus a MEMS based platform for detecting E. coli we use the below flow chart to 
illustrate the time difference in the two methods [9]. 
 
Figure 16: Gold standard agar plate culture compared with MEMS platform Ref. [9] 
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One of the important challenges in agar plate culture is the need for a minimum amount 
of sample to culture, this lack of minimum leads to false positive results from 7.09% to 
21.06% as per data from United States CDC. From the above illustration of the process 
flow of agar plate culturing we see that there is need for clinical expertise to perform the 
Giemsa staining (The stain is a composite of Methylene Blue, Eosin and Azure B) 
followed by MacConkey plates and the duration of this process if almost two to three 
days. On the contrary, when we see the MEMS based method, there is no need for any 
large instrumentation set up. As previously indicated, both RT-qPCR and ELISA 
methods need large device set up or multiple steps to prepare and wash the sample, all 
which are time and capital intensive. In the method described above, which takes about 
half an hour, we need to inject E. coli in blood sample into the channels of the 
microfluidic device. The surface chemistry of the device has lipo-polysaccharide binding 
protein anti-body, which is then washed with Phosphate buffered saline using a injection 
machine and then the analysis is done using fluorescence imaging. The PBS wash step 
ensures that any un-captured bacteria are washed away from the surface. In the below 
figure we describe the micro-fabrication of the microfluidic device using PMMA, DSA 
and glass slide, forming the chip [9]. 
 
Figure 16a:  Device micro-fabrication B. surface chemistry of the channels and c. imaging. Ref [9] 
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Chapter 4 
Nanoplasmonic Detection of HIV  
4.1 Introduction 
In an effort to have a highly multiplexable platform, we use the method of LSPR to 
quantitatively detect various intact HIV and its subtypes like A, B, C, D, E, G and panel. 
In the previous chapter we have seen how E. coli can be captured using LBP surface-
chemistry on microfluidic channels. We also perform surface characterization using 
Atomic Force Microscopy when the surface has polystyrene, Poly-L-Lysine, and Gold 
nanoparticle (AuNP). In the below diagram we illustrate [11] the overall surface 
chemistry of the LSPR plates for detecting HIV subtypes.  
 
 
Figure 17a: Overall surface chemistry of the plate, b. specific binding sequence. 
 
In the above figure we see that over a glass slide, a layer of Poly-L-Lysine is coated, on 
top which, gold nanoparticles have been incubated. This layer serves as the substrate for 
attaching 11-mercaptoundecanoic acid (MUA) and N-ethyl-N’- (3-dimethylaminopropyl) 
carbodiimide hydrochloride  (EDC)- N-hydroxysulfosuccinimide (NHS) buffer. These 
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chemicals serve as a binding site for NeutrAvidin (NA) to attach. NA is the last step that 
holds on to the anti-glycoprotein (gp) antibody that can bind with the HIV Virus [11].  
4.2 Materials 
The materials used are as follows: Ethanol 200 Proof from Fischer, PBS from Invitrogen, 
Polystyrene plates from Corning, MUA from Aldrich, EDC from Aldrich, NSA from 
Aldrich, BSA (Bovine Serum Albumin) from Sigma Aldrich, MES and PLL from Sigma, 
AuNP from TedPella, NA from Pierce Biotechnology, Biotinylated goat anti-Human 
Immunodeficiency Virus glycoprotein 120 polyclonal AB was purchased from Abcam. In 
the below flow chart we describe the surface chemistry in detail [11]. 
 
In the above process, we begin by first evaluating if the surface binding of AuNP over the 
PLL layer is uniform or not, by using a wavelength shift that is a linear function of 
concentration which was observed as plotted in the below graph. Two incubation times of 
24 hours and 72 hours were used to comparison. It was found that there was a statistically 
same correlation for the two time periods of incubation of PLL concentration ranging 
from 0.001 to 0.01 mg/mL of PLL in PBS [11].  
AuNP modification 
40uL of AuNP seeding on surface Overnight incubation at 4C 
Incubate with PLL to form amine groups at terminal position 
0.01 mg/mL to 0.1 mg/mL PLL in PBS  Incubate at 4C overnight (8 hours) 
Surface Modification for LSPR plate for HIV quantification 
200 Proof Ethanol wash of the polystyrene surface Wash with distilled water and dry with N2 gas 
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Figure 18. PLL concentration versus Wavelength in nm for 10 different PLL concentration 
 
 
          
 
Figure 19. PLL and AuNP binding 
From Figure 18 we can see that there a linear dependence on the lambda shift and PLL 
concentration as it is varied from 0.01 to 0.1mg/mL. Figure 18 b shows the change in 
extinction coefficient as we increase the concentration of PLL. Antibody surface 
chemistry and immobilization was carried out following the surface modification using 
PLL and AuNP. The AuNP layer is incubated with 11-mercaptoundecanoic acid (MUA) 
in ethanol solution. The reason we use 11mercaptoundecanoic acid (MUA) is to form 
carboxyl functional groups that can act like a cross-linking agent [11]. 
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Figure 20: Chemical structure of MUA depicting the Carboxyl terminal group 
We then add N-ethyl-N’- (3-dimethylaminopropyl) carbodiimide hydrochloride  (EDC)  
in MES buffer, so that there can be a reaction with the COOH- group to form a amine 
intermediate.  
 
Figure 21: Chemical structure of EDC with amine intermediate group 
To this intermediate we add N-hydroxysulfosuccinimide as a stabilizing agent. Following 
this incubation we add 100uL of NeutrAvidin (NA) with a concentration of 0.1mg/mL so 
that we can bond AB to the surface. The addition of NA helps to properly align the AB 
over the surface, thus improving the capture efficiency of the virus. A blocking agent is 
also incubated, in order to prevent any non-specific adsorption by using bovine serum 
albumin at 10% concentration and incubated at 39.2 degree Fahrenheit for 60 minutes. 
After the addition of albumin, we add biotinylated anti-glycoprotein 120 AB to attach to 
the biotin sites in the NA. 
 
Figure 22. NeutrAvidin from ThermoScientific. 
BAMM Labs obtained from the AIDS Research and Reference Reagent Program at the 
National Institute of Health samples of HIV and its most prevalent subtypes of A, B, C, D 
, E, G, and strains CRF01_AE and CRF02_AG. These patient samples were from both 
Uganda and many hospitals within the United States of America and were cultured using 
 34 
a standard cell culture protocol. Those cells with round nulcei were cultured, a.k.a. 
Peripheral Blood mononuclear cells, instead of those with lob shaped nucleus. Most cells 
of the human immune system like, lymphocytes and macrophages are typically PMBC 
type. Due to the difference in density of various types of cells found in blood, we employ 
the famous Ficoll Hypaque density gradient centrifugation (FHDGC) method to 
obtain HIV-1 negative cells. Due to lower mass density mononuclear cells and platelets 
are collected on top after the centrifugation.  
 
Figure 23: Ficoll Hypaque density gradient centrifugation  
After 72 hours, Phytohemagglutinin (PHA), which is  a lectin or a carbohydrate binding 
protein found in plants is stimulated, HIV-1 –ve Peripheral Blood mononuclear cells are 
co-cultured with HIV +ve Peripheral Blood mononuclear cells, which consist of Roswell 
Park Memorial Institute (RPMI) 1640  along with L-Glutamine, an essential amino acid 
and the most freely found amino acid in human blood along with  20% of fetal bovine 
serum which is obtained from blood after natural coagulation- FSA also contains a 
majority of BSA by content, penicillin obtained from the penicilium fungi, streptomycin- 
the remedial drug for Tuberculosis (TB) , (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid ) (HEPES) buffer and recombinant human interleukin-2 (IL-2) which helps in the 
proliferation or increasing the number of T-cells as an immune response is used during 
cell culture. The entire cell culture was performed under 5 percent of carbon dioxide 
atmosphere at 37 degree C and there was bi-weekly replenishments of the cell media. 72 
hour PHA stimulated HIV-1 +ve Peripheral Blood mononuclear cells were added every 
seven days and the supernatant was taken for p24 antigen test, which is done as a 
standard test for HIV detection. In the below diagram we illustrate the detailed structure 
of an HIV [11,12] 
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Figure 24: Human Immunodeficiency Virus 
Using the above-mentioned protocol for cell culturing, different subtypes of HIV were 
cultured in PBMC.  
4.3 Experiment 
We collected HIV infected patient blood samples from the Massachusetts General 
Hospital. Before spiking whole blood with HIV, we performed a reverse transcriptase 
quantitative polymerase chain reaction test to quantify the amount of various HIV 
subtypes. The following dilutions were made: HIV A subtype of 6.55 E8 copies/mL, 
Subtype B of  6.37 E8 copies/mL, Subtype C of 20.9 E8 copies/mL, Subtype D of 7.00 
E8 copies/mL, Subtype E of 8.39 E8 copies/mL, Subtype G of 6.53 E8 copies/mL, HIV 
Panel of 14.80E8 copies/mL. Guanidine Isothiocynate was used for lysis to extract RNA 
for HIV stock quantification [11].  
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Figure 25: QIAamp Viral RNA Mini Kit 
 
4.4 Results 
After the viral load quantification using the RT-qPCR, stock solutions of HIV- A, HIV-B, 
HIV-C, HIV-D, HIV-E, HIV-G, HIV-Panel were spiked into whole blood serum so that 
the final concentration cab range from 50 to 1 million copies per mL.  100uL of HIV 
spike whole blood was pipetted into each surface modified wells and left for incubation 
for 60 minutes at 39 degree F. The control group was whole blood without any HIV 
spiked into it [11]. 
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Figure 26 a. Wavelength peak for each surface modification b. Wavelength shift (nm) after 
HIV spiking c. Limit of detection for each HIV subtype [11]. 
In order to make measurements using the Varioskan, after each step of the surface 
chemistry we wash the wells three times each with 100 uL of Phosphate buffered saline 
and then add PBS fourth time for making the measurement. This is a standard protocol 
while performing the surface chemistry. For every HIV subtype (A, B, C, D, E, G, 
Panel), we subtract from the corresponding control group spectra, to get the shift in 
wavelength before and after HIV spiking and the change in extinction intensity +/- 
standard error of mean (SEM). Another set of separate Reverse transcriptase quantitative 
polymerase chain reaction was also performed to reduce any dilution errors. We use a 
fixation solution of Paraformaldehyde (PFA) before the HIV detection step over the 
captured virus. From figure 26a. we see that Au has a peak at 518 nm and when we 
incubate AuNP over PLL, the peak is shifted to about 546 nm and all the other layers 
starting from MUA, ED/NHS, NA, AB gave a peak shift to 552 nm [11]. When control 
(no HIV blood sample) was added, there was no significant or observable peak shift. 
Figure 26b shows the peak shift when HIV infected samples are added. The 
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corresponding values displayed on the graph are: 9.3 +/- 1.2 nm for Subtype A, 5.4 +/- 
1.1 nm for Subtype B, 4.4 +/ 0.5 nm for Subtype C, 7.8 +/1.1 nm for Subtype D, 6.3 +/- 
0.8 nm for Subtype E, 5.8 +/- 0.7 nm for Subtype G and finally 6.9 +/- 1.2 nm for 
Subtype Panel of HIV. Figure 26c shows us the lower limits of detection and the 
corresponding peak shift of wavelength. For HIV subtype A, B, C, D, E, G and panel the 
following lower limits of detection in copies/mL were obtained: 1346, 10609, 14942, 98, 
120159, 404 and 661. 
 
Figure 27: RT-q-PCR quantification and the obtained wavelength shift in nm. 
 
From the above plots we see that the lowest limit of detection by the Reverse 
transcriptase quantitative polymerase chain reaction, which is considered the gold 
standard method, the value is about 50 copies/mL. Any result that was below this lower 
threshold was also reported as 50. After the above measurements were done, surface 
characterization was also done using atomic force microscopy. In order to better 
understand the physics and working of a scanning force microscope, we use the below 
illustration Figure 28. The AFM has a spatial scanning resolution of 5 um x 5um, that can 
be used to analyze the surface roughness. After performing the first two surface 
modification on polystyrene by adding Poly-L-Lysine [11] and AuNP the surface 
roughness changed 18.93 +/- 1.35 nm. It must be noted that this value is the root mean 
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square value over multiple random 5x5 um surface samples, and the analysis was done 
using the non-parametric Kruskal Wallis one way ANOVA. 
 
Figure 28a. Working of Atomic Force Microscope for surface characterization in LSPR 
platform. Ref [19] 
 
In order to make the measurements we used the Asylum-1 MFP-3D AFM system which 
has been depicted below. 
 
  
Figure 29a. Asylum MFP-3D Atomic Force Microscope. Ref [19] 
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The surface roughness before the PS surface was modified with PLL was observed to be 
around 2.50 +/- 0.10 nm RMS. When we incubated the surface with Poly-l-Lysine 
overnight at 4 degree C, the roughness changed to 2.40 +/- 0.20 nm, which is a very small 
difference in the RMS roughness. However, after we incubate AuNP overnight at 4 
degree C, the surface roughness increased to 4.70 +/- 0.2 nm. For (n=8, p > 0.005) 
indicated that there is no statistically significant difference, however for (n=8, p< 0.005 ) 
is statistically different for AuNP modification. The uniformity of coating was computed 
using Image-J software with a value of 83% on the LSPR platform. This implies that 24 
hour incubation of PLL followed by AuNP [11] gave a very dense coating which was 
needed for further surface modification. After the surface were modified, we incubate the 
platform at 39 degree F and there was no coffee ring effect observed, which is otherwise 
seen when liquids evaporate from a surface and leave a stain mark behind. 
After performing surface roughness estimation using the AFM, we also perform a 
Scanning Electron Microscopy of the HIV that was captured using the LSPR platform. 
Each polystyrene well had a surface area of approximately 4 million square microns. 
After the surface modification was done using MUA, EDC/NHS, NA, AB [11] we 
imaged the surface using SEM at 4.7 mm working distance and 4000 volts of exciting 
voltage.  
Numerical estimation and theoretical modeling of the HIV capture over surface modified 
Polystyrene. From the research published by Decuzzi et.al [7], we obtain the following 
mathematical models: 
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In the above expression, N denotes the number of AuNP that are on the active area of 
consideration, V is the volume in milliliters of the of the Virus solution in blood and V= 
0.1 mL, C is the number of copies of the HIV present per milliliter ranging from 50 to 
10
6
,    is the beam area of the scanning optical beam of about 3.1 mm
2
, A is the entire 
surface area of the Polystyrene well of about 37 mm
2
,   denotes the capture efficiency of 
the HIV and its subtypes which is typically greater than 70%, 
  
  
 is the ration of surface 
area of HIV (kappa) to that of AuNP (K). The notations          are the receptor and 
ligand mass density, whereas   
  represents the association constant of the virus over the 
surface modified PS at no load condition of receptor-ligand pair. The shear mechanical 
stress experienced at the walls is denoted by   ;    and    are the coefficients that 
depend on the shape of the ligand. The bond length that is formed between the ligand and 
the receptor is denoted by         . The Boltzmann constant is represented using    
and the half-length of the HIV is represented by the letter ‘a’,     is the separation 
between the virus and the antibody coated surface at thermal equilibrium,    is the radial 
length of the Virus,   denotes the aspect ratio of the virus = 1, which is defined as the 
ration of half length a to b of the major and minor axes. T= 300K is the temperature and 
ml and Ka are not numerically known for the virus. From the experiments performed [11], 
we obtain a value for   as 70% to 78% when the blood is spiked with HIV, for the 
microfluidic chips with surface chemistry as described previously. The data obtained 
from experiments on the number of virus captured, fits well with the above model 
described. 
We also summarize the data obtained by the experimental maximum data method in the 
below table. The results were also corroborated, by taking patient blood samples with 
those infected with HIV, we took n=8, and used the LSPR platform to determine [11] the 
corresponding peak shifts in the samples. The highest peak was given close to 2.8 nm at 
3900 copies/mL and the lowest peak was at 1.3 nm for 481 copies/mL 
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Table 2: HIV Subtype compared with corresponding maxima and minima peaks 
HIV Subtype Highest Peak Highest 
Concentration 
(copies/mL) 
Lowest Peak Lowest 
concentration 
(copies/mL) 
A 5.2 nm 6.5E05 1.3 nm 50 
B 4.7 nm 8.3E05 2.5nm 89 
C 6.3 nm 1.3E06 2.7 nm 50 
D 4.3 nm 3.8 E06 1.7 nm 98 
E 4.7 nm 1.3 E06 1.2 nm 50 
G 4.8 nm 1.1 E06 2.0 nm 404 
Panel 6.5 nm 2.9 E06 1.5 nm 101 
 
 
The proposed LSPR platform can only be deployed in resource constrained setting if it 
has a proven high repeatability and reliability.  
In order to compute these important parameters we define the below mathematical 
expression: 
               
                                         
                                             
       
 
Using the above equation [11], we compute the repeatability for different concentrations 
ranging from the minimum copies/mL to the maximum copies/mL and has been 
summarized in the below table. 
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Figure 30. Repeatability plot. Ref [11] 
 
 
HIV Subtype Repeatability Highest 
concentration 
(copies/mL) 
Lowest 
concentration 
(copies/mL) 
A 72 – 90% 6.5E05 50 
B 74.9- 89.9% 8.3E05 89 
C 75-87.9% 1.3E06 50 
D 64-90% 3.8 E06 98 
E 59-85% 1.3 E06 50 
G 74.9-83.9% 1.1 E06 404 
Panel 74.9-88.9% 2.9 E06 101 
Patient Sample 59-77.9% 3910 481 
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The repeatability factor was computed for the wavelength shifts for the various subtypes 
of HIV under consideration at different concentrations ranging from minimum 50 copies 
to E05 copies/mL. The plot in Figure 30 shows that the values lie between 59% to about 
91.9% for various copies/mL values of HIV spiked blood [11] and patient blood obtained 
from the Massachusetts General Hospital.  
By utilizing the method of mathematical curve fitting we can use this data to compare 
with actual HIV infected patient blood samples. The quantitative enumeration is possible 
using the extinction intensity analysis by this method. In the below figure, we see than 
patient blood sample [11] (whole blood) are evaluated using LSPR platform. From this 
method the value reported was from 2.2 log base 10 copies/mL to 3.69 log base 10 
copies/mL in patient samples. The same blood sample when analyzed using Reverse 
Transcriptase quantitative polymerase chain reaction, report a viral load of 2.69 log base 
10 to 3.59 log base 10 copies/mL. In the adjacent figure below, Bland Altman ANOVA 
between the LSPR platform and Reverse Transcriptase quantitative polymerase chain 
reaction method based counting are shown, and the results do not indicate any 
“systematic bias” in the two methods. 
 
Figure 36: Data from HIV patient samples compared with RT-qPCR and LSPR[11] 
 
In the process of performing the LSPR measurements, we must also be careful about the 
effect of neighboring NP on the extinction spectrum obtained. In recent papers, it has 
been reported that the arrangement of AuNP can create some regional hot spots where the 
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SPP can be amplified due to very small inter-NP distance. Such amplifications [11] can 
also be used in the detection of Adenovirus which is about 100 nm is size and are double 
stranded DNA viruses unlike HIV. The effective refractive index also affects such a 
detection mechanism.  
4.5 Remarks 
Before analyzing the data from curve fitting method and experimental data maximum 
technique the following observations are made [11]: 
[1] In the method of curve fitting, the entire spectrum was analyzed due to small 
wavelength shifts at low concentrations of the HIV. In comparison with 
experimental data maximum (EDM) method and curve fitting (CF) method, the 
CF method is more suitable if we use samples having low amounts of virus 
content[11]. 
[2] 216 spectral plot [11] with only surface chemistry with antibody (Ab) and 216 
spectral plots with the HIV infected patient blood samples after surface chemistry 
were analyzed. In order to get the difference or the peak shift, we subtract every 
plot after adding HIV from the control.  
[3] 9 out of 216 wells indicated a negative shift of peak, which means that some noise 
was introduced during the sample preparation step. Such wells were discarded 
from data analysis [11]. 
[4] 4 wells had a -1 nm change, which were also discarded from the analysis, due to 
potential noise from surface chemistry steps [11]. 
[5] 1 well from 50 and 1 well from 100 copies/mL concentration had a shift larger 
than the rest from its category + 1 SEM, these two were also rejected. 
[6] In case a virus is not trapped on the surface modified LSPR plate, there is no 
expected shift. However in case of 10 wells, there was shift that was lesser than 
the device resolution of 1 nm, and thus these 10 were also discarded [11]. 
 
  
 46 
Chapter 5 
Pathogen detection 
5.1  Interferon gamma capture for tuberculosis diagnosis 
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major global 
health problem with an estimated 8.8 million new active TB cases, and approximately 1.1 
million deaths in 2011 (WHO, 2011b). Among these new TB cases, the majority occurred 
in the South-East Asia region, which accounted for 40% of the global incidence. Further, 
only 65% (5.7 million) of the estimated TB cases in 2010 were reported, indicating the 
need for improved diagnosis [43]. The WHO estimates that there will be more than 2 
million new cases of MDR-TB between 2011 and 2015 (WHO, 2011c). These numbers, 
combined with increasing spread of infection with multi drug-resistant (MDR), 
demonstrate an urgent need for new approaches for early diagnosis, therapy monitoring, 
and disease supervision. Diagnosis of TB infection (active or latent) is essential not only 
for treatment of the infected individual, but also for controlling its spread among various 
populations. In TB endemic areas, TB control programs aim to treat active TB patients 
rather than individuals with latent TB infection (LTBI),which is only evidenced by the 
immunological responses to MTB proteins [44]. Although LTBI individuals are not 
infectious, their identification is equally important since 10% of these individuals, 
particularly the immunosuppressed, can subsequently develop active tuberculosis. The 
routine diagnosis of active TB infection employs various approaches including smear 
microscopy, culture of MTB bacilli, detection of MTB nucleic acids (NAATs, nucleic 
acid amplification tests), and clinical symptoms. Conversely, LTBI is identified via 
tuberculin skin test (TST) and interferon gamma (IFNγ) release assays (IGRAs). 
However, current TB diagnosis is limited by three primary limitations: 
1) low specificity of clinical diagnosis,  
2) unavailability of high performing diagnostic methods in developing world 
laboratories, 
3) incapability to monitor patient compliance to the 6–9 month long therapy. 
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Although there is an unmet need to develop a simple, inexpensive, sensitive and 
portable assay for the detection of active MTB infection, and for the differentiation of 
active TB from LTBI at the point-of-care (POC), where sustainable financial support, 
laboratory infrastructure, and well-trained operators are limited [40]. 
Interferon-gamma release assays 
IFN-γ release assays have been developed and implemented since 2001 with varying 
degrees of success (39). These tests measure T cell release of IFN-γ (host cellular 
immune response) upon stimulation of whole blood with MTB-specific antigens, 
including early-secreted antigenic target 6 (ESAT6) and culture filtrate protein 10 
(CFP10) and TB7.7 (an additional antigen used in modified IGRA kits). IGRA assays 
are available in two formats, ELISA and enzyme-linked immunospot assay 
(ELISPOT). ELISA quantifies the concentration of IFN-γ, while ELISPOT test 
counts the number of IFN-γ-producing antigen-specific T lymphocytes. Although 
these assays are not affected by prior BCG vaccination as the antigens are absent in 
all BCG strains, they cannot distinguish individuals having LTBI from those with 
active disease [41]. In addition, systematic review and meta-analyses have shown that 
neither of the IGRA assays has better sensitivity than TST in detecting active or latent 
TB infection in HIV-infected individuals. Thus IGRA assays cannot be used to rule-
in or rule-out active TB cases, especially in HIV-infected individuals in high-burden 
settings. This limitation has led a WHO expert group to discourage the use of IGRA 
assays for active pulmonary TB diagnosis in low- and middle-income countries. 
Furthermore, the assay takes 24 h to produce results and requires significant 
instrumentation and well-trained personnel [45]. 
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How IGRA is performed
Figure 37: blood cells are incubated with various tuberculosis-specific antigens. In response to the antigens, 
effector T cells produce interferon-gamma, which is measured quantitatively and qualitatively by either 
enzyme-linked immunosorbent or enzymelinked immunospot assay 
LSPR detection 
We have been developed LSPR optical technology also to detect MTB specific 
antigens (e.g., CFP-10 antigen) in tissue fluid. In this immunobased detection method, 
monoclonal anti-CFP10 was used  as a sensitive TB marker. The biosensing surface, 
was modified layer-by-layer for antibody immobilization. To modify the surface we 
have followed the same protocol as for the HIV detection: 0.05mg/ml PLL spiked in 
PBS, overnight incubation, 50 mL AuNP overnight incubation, 1mM MUA in PBS 3 
hours incubation, 191,7mg EDC+ 57,55mg NHS in MES buffer overnight incubation. 
For the antibody binding we use 100uL of Protein G with a concentration of 
0.1mg/mL . The addition of Protein G helps to properly align the Ab over the surface, 
thus improving the capture efficiency of Interferon γ cytokine. A blocking agent was 
also incubated, in order to prevent any non-specific binding, by using 10% BSA 
(bovine serum albumin). Following this incubation we added 100uL of antibody anti-
CFP10 that attach with Protein G.   
After the antibody incubation the biosensing surface is ready for the interferon 
gamma detection. As a first step we tried low end measurement, so that we spiked 
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INF- γ in PBS. Each wells of our plate was filled with different INF- γ  concentration, 
from 1pg/mL to 1fg/ml and for each concentration we added 6 replicates. 
In order to get a better value for the detection limit of Interferon Gamma, we decided 
to repeat the experiment and add more date point to analyze the gap in the graph of 
extinction intensity vs. wavelength, between the range of 100 fg/ml to 500 fg/ml of 
IFN-y. We show here an example of the dilution we have done. Using 10pg/ml stock 
solution of IFN-y, we performed the below dilution steps in order to arrive at the 
desired concentrations of 100 fg/ml, 200 fg/ml, 300 fg/ml, 400fg/ml and 500fg/ml.  
Concentration Dilution Computation:           
10pg/ml × V=500fg/ml × 5ml,   V=0.25 ml of Stock + 4.75 ml PBS, and so on for 
all the other concentration. We then incubated the plate for 1 hour. Following the 
incubation, we washed with PBS three times, and allowed the plate to incubate with 
PBS. We finally analyzed the plate using the Varioskan Flash spectral scanning 
multimode reader. The measuring mode was set to detect Extinction changes per 
wavelength, swept from 400 nm to 700 nm in steps of 1 nm resolution. This spectral 
analysis is done for all the 96 wells. 
 
 
Figure 38: Matlab plot of the wavelength shift peak for different  INF-y concentrations analyzed 
with Varioskan scan. 
 50 
The above graph represent the wavelength shift of the concentration that we have 
used to study the platform response. The red area highlight in the plot demonstrates 
the response of control sample. PBS without IFN-Ɣ was used as a control. All the 
concentration are referred to the control, those with higher peak shift are the ones we 
can consider detected by the platform. The platform cannot detect the concentrations 
with a wavelength shift lower than the control, because they are hidden from the 
noise. IFN-Ɣ concentrations ranging from 500 fg/mL to 1 ng/mL demonstrate the 
linear dynamic range of nanoplasmonic platform. The error bars represent mean ± 
standard errors of the mean (SEM). From this results we can find that the limit of 
detection for IFN-Ɣ spiked in PBS is 400 fg/ml.  
As a final step we spiked interferon gamma in serum with concentration from 
100ng/mL to 1fg/ml, the results are shown below. 
 
Figure 39: Matlab plot of the wavelength shift peak for different  INF-y concentrations spiked in 
serum analyzed with Varioskan scan. 
After analyzing the results we have found the platform limit of detection for INF-y 
spiked in serum that is 500 fg/ml, while IGRA assay has ng/ml as limit of detection. 
In the table below we have summarized the differences between IGRA and LSPR 
test.  
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IGRA LSPR 
Time consuming assay (24 h) Rapid: 1h for incubation and 10 min for 
analysis 
Requirement for pre-processing of blood 
samples 
No requirement for pre-processing 
 
Requires significant instrumentation Easy to use 
Expensive Inexpensive assay 
Limited to Children younger than 5 years 
old Persons recently exposed to M. 
tuberculosis 
Lower limit of detection (down to fg 
level), so it can be used for Children 
younger than 5 years old and persons 
recently exposed to M. tuberculosis 
 
 
LSPR-based immunosensors can also be adapted to sense other antigens and 
pathogens by altering the detection molecules (e.g., antibodies), thus offering highly 
versatile platforms. Although LSPR immunosensor offers advantages of simplicity, 
small sample consumption, label-free, high sensitivity, specificity, and reusability, it 
requires a well-equipped laboratory infrastructure. Thus, portable and inexpensive 
SPR-based MTB biodetection systems are needed to minimize laboratory requirement 
for POC testing. That is why we are trying to improve this platform and make it 
portable (see chapter 6). 
 
 
 
 
 52 
5.2 Kaposi’s sarcoma virus capture and detection  
 
Figure 40 kaposi’s sarcoma associated herpesvirus  
 
KSHV (kaposi’s sarcoma associated herpesvirus ) is a virus belonging to the family of 
herpesviruses, which has seven other members that infect humans. Herpesviruses are 
a group of similar viruses, most of which are extremely common infections that we 
have probably been exposed to. Some herpesviruses cause diseases while infection 
with others generally do not cause symptoms. The lay term "herpes" usually refers to 
herpesvirus type 1, which causes cold sores on the lips (more than 90% of people are 
infected with herpesvirus type 1), or herpesvirus type 2, which is a sexually 
transmitted disease that causes "cold sores" on the genitals (about 25% of US adults 
are infected with herpes type 2). Since both herpes type 2 and KSHV are sexually 
transmitted (at least in developed countries), they primarily infect adults. KSHV was 
discovered in 1994 and so, our understanding of it is just beginning. KSHV is 
different from herpes type 1 and 2 in that it causes a blood vessel cancer called 
Kaposi's sarcoma (KS), a lymphoma (a cancer of the lymphocyte) called body cavity-
based lymphoma and some forms of severe lymph node enlargement, called 
Castleman's disease. Some early scientific reports suggested that it might also cause 
multiple myeloma, however, many scientists now believe that this is very 
unlikely[46]. 
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Figure 41 : A photomicrograph of KS in the skin. Blood cell accumulate in the tumor, shown 
here in red 
KSHV is completely different from the HIV virus which causes AIDS, although 
KSHV-related diseases frequently occur among AIDS patients. The rates of KSHV 
infection in the general population of Mediterranean countries (Italy, Greece, Israel, 
Saudi Arabia) are higher than in North America and Northern Europe where KSHV 
appears to be rare among the general population. In surveys in the UK, France, 
Switzerland, Denmark and Sweden, the prevalence ranges from 3–7%, also 
depending on the assay. KSHV prevalence rise dramatically in countries in Southern 
Europe. In Italy and Greece, prevalence’s of up to 35% are found among blood 
donors, and a marked regional variation has been noted. Antibodies to KSHV are 
found in 0–29% of the subjects In Africa, in 6–53% of tested samples such as HIV 
negative patients, antenatal mothers, hospitalized patients and unknown sources. In 
several respects the global patterns of KSHV infection appear to be similar to those of 
the hepatitis B virus although we are still at an early stage of understanding the 
epidemiology of KSHV [47].  
Kaposi’s sarcoma virus detection with LSPR platform 
A major challenge in the diagnosis of KS is the existence of a number of other 
diseases with similar clinical presentation and histopathological features, requiring 
the detection of KSHV in a biopsy sample. Infection in immunocompetent individuals 
results in the generation of pathogen-specific CD8+ T-cell responses that control 
Kaposi sarcoma herpes virus replication and prevent its progression to neoplastic 
disease. 
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We prepared LSPR plate for Kaposi’s sarcoma virus infected patients. We 
functionalized the biosensing surface, for the antibody immobilization following the 
same step as for the interferon gamma capture. After protein g incubation, we filled 
half of the plate with 100 μL of 5 μg/mL  Antibody KSHV-HHV.8 ORF K8 1.A and 
the other half with KSHV-HHV.8 ORF K8 1.A/B, that are mouse monoclonal 
antibody to lytic cycle. We wanted to try both specific antibody to understand which 
one is better for our application. The antibody incubation is one hour, after the 
incubation we washed it 3 times with PBS and the plate is ready for the virus 
sampling. We have performed the following sampling virus step: 
1- Take out all PBS from the wells by pipetting or aspiration. Without touching the 
bottom of the well. 
2- Prepare virus dilutions spiked with PBS and artificial saliva (the artificial saliva 
receipt is reported in the Appendix B). The concentration range we used was from 
10 to 10^6 copies/mL with the following data point:  
10 -20 -50 -100 -10^3 -10^4 -10^5 -10^6 copies/mL. 
3- Add 100 µL of each virus dilution to the wells, with 8 sample replicates to 
minimize the dilution inaccuracies. 
4- Seal the plate and its lid with parafilm, and cover with aluminum foil to incubate 
it at 4°C for 1 hour  
5- After the incubation, wash each well with 100 µL of PBS three times, and take 
out all solutions from each well. 
6- Add 100 µL of 3% paraformaldehyde (PFA) in PBS to each well, and incubate it 
for 10 minutes at room temperature. 
7- wash each well with 100 µL of PBS three times and add 100 µL of PBS to each 
well for the measurements. 
8- Before the measurements, the plate is  kept at +4C. 
We took the measurement with the Varioskan Flash spectral scanning multimode 
reader. Also for this experiment we set the measure mode to detect extinction changes 
per wavelength, swept from 400 nm to 700 nm in steps of 1 nm resolution. We 
present the results in the graph below. 
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Figure 42 a) Wavelength shift(nm) after virus spiking for each concentration b)repeatability of 
the measurement for the different concentration. 
From this results we can clearly understand that our platform limit of detection is 
1000 copies/mL, because lower concentration have a peak shift smaller than the 
control, that is PBS without virus.  We have already define the repeatability in chapter 
4, and we have computed it here for the wavelength shifts of the different 
concentrations ranging from 10 to 10^6 copies/mL . The plot in figure 42 b) shows 
that the values lie between 53% to about 92% for various copies/mL values. Although 
the exact number of viral copies per cell has not been determined yet, real-time PCR 
was recently, used to detect and quantify KSHV, and several reports have 
demonstrated that number of viral copies varied depending on the disease and its 
stage. However, to date, only 1 report has used real-time PCR to compare the number 
of viral copies in samples from KS lesions, and this study was conducted on a limited 
number of samples. In this scenario our LSPR platform is a good candidate for a 
Kaposi’s sarcoma virus diagnosis.  
5.3 Carbamazepine capture for epilepsy treatment 
Epilepsy is a brain disorder in which clusters of nerve cells, or neurons, in the brain 
sometimes signal abnormally. In epilepsy, the normal pattern of neuronal activity 
becomes disturbed, causing strange sensations, emotions, and behavior, or sometimes 
convulsions, muscle spasms, and loss of consciousness. During a seizure, neurons 
may fire as many as 500 times a second, much faster than normal. In some people, 
this happens only occasionally; for others, it may happen up to hundreds of times a 
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day. People living with this nerve disorder have seizures that can affect their mental 
and physical functioning.  2.2 million Americans and 50 million people in the 
worldwide have epilepsy although there are medicines to treat epileptic seizures 
nearly one in three patients has a severe side effects from the medicines, these include 
blurry or double vision, discomfort, fatigue, sleepiness, unsteadiness, and stomach 
upset [48]. This side effects can be reduced by adjusting drug dosage and timing, 
using lab test, however these tests can be inconvenient and costly. With our LSPR 
device we can measure anti-seizure drugs in the blood, that allowed patients and their 
caregivers to manage their treatment anywhere. By far the most common approach to 
treating epilepsy is to prescribe antiepileptic drugs. Carbamazepine are the most 
common anti-seizure medication.  
LSPR technique for carbamazepine capture  
We prepared the LSPR plate for carbamazepine detection following the same step as 
before. The antibody used is the Anti-Carbamazepine antibody (ab30435), his target 
are the carbamazepine. Carbamazepine coupled to BTG through a spacer attached to 
a 5 carboxamide group and this binding allow us to detect them.  
The antibody incubation is 1 hour, after that we washed it 3 times with PBS and we 
added the carbamazepine spiked in serum with the following concentration range 
from 0.5 μg/mL to 30 μg/ml. Another hour of incubation and the plate is ready for the 
measurement that have been taken with the Varioskan scan reader. 
The results are plotted in the graph below. 
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Figure 43: Matlab plot of the wavelength shift peak for different  CBZ  concentrations analyzed 
with Varioskan scan 
 
This results clearly demonstrate that the limit of detection of our plate is much lower 
than the minimum concentration that we are interested in, 0.5ug/mL is the minimum 
we have tested.  
Optimum seizure control in patients on carbamazepine monotherapy is most likely to 
occur at plasma carbamazepine level of 04-12 µg/mL .  The absorption rate of this 
drug largely change from patient to patient. After oral ingestion, carbamazepine is 
rapidly absorbed ( T-max is formulation-dependent) with a bioavailability of 75–85 
%. Its volume of distribution is 0.8–2.0 L/kg, and plasma protein binding is 75 %. 
The maximum absorption is reached 6 or 8 hours after the drug administration, so that 
with our platform is possible to detect patient under carbamazepine drugs even after 
12 hours from the drug administration. More over carbamazepine is excreted by the 
kidney and metabolized by the liver and dosages may need to be lowered in patients 
with liver or kidney dysfunction, even in this case we can detect if the drug 
concentration in the blood.  
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In conclusion we can say that innovative solutions utilizing recent advances 
microfluidic technologies are envisioned to assist the demand for accessible and 
affordable healthcare for infectious and chronic diseases. This present significant 
challenges for providing high-value and effective healthcare. Traditional approaches 
are expanding to include point-of-care (POC) diagnostics, bedside testing, and 
community-based approaches to respond to these challenges. Highly sensitive and 
specific lab assays such as cell culture methods, polymerase chain reaction (PCR), 
and enzyme-linked immunosorbent assay (ELISA) are available for diagnosis of 
infectious diseases in the developed world. They require sample transportation, 
manual preparation steps, and skilled and welltrained technicians. These clinical 
conventional methods provide results in several hours to days, precluding rapid 
detection and response at the primary care settings. Another diagnostic challenge is 
identifying multiple pathogens. Our microfluidic platform respond to these 
challenges. As we have demonstrate it is a rapid assay: 1h for pathogen incubation 
and 10 min for analysis, easy to use and inexpensive. Moreover until now, there is no 
general biosensing platform for detection of multiple pathogens, allergens and drugs 
that can be adaptable to POC settings due to significant technical and biological 
challenges. Here, we presented a widely applicable platform that can capture, detect 
and quantify multiple intact viruses including  those we analyzed before and we have 
also tested and verified the efficiency of the platform for Hepatitis B virus, 
Trichomonas vaginalis virus and Dengue virus. 
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Chapter 6 
Portable Localized Surface Plasmon Resonance  
Background 
The increasing costs associated with primary health care in developing countries has led 
to a significant amount of research in the direction of low cost technologies for disease 
diagnosis that can be used at the point-of-care setting. There are several tecnhieqs that 
can be used for pathogen detection such as Surface Plasmon Resonance, Localized 
Surface Plasmon Resonance, Piezoelectric resonators etc. One of the most promising 
method that has a very sensitivity and reliability in detecting pathogens is LSPR. Present 
Commercial Off The Shelf (COTS) based devices to perform spectroscopic studies cost 
about US 40,000 or more. This method of detection is very well suited for clinical 
settings with considerable infrastructure. However, in order to deploy a detection 
platform based on LSPR, the primary challenge is to make the device compact and 
affordable. 
Work done  
In order to develop microfluidic chips that can be used for multiple disease causing 
pathogen detection at the point-of-care using the method of LSPR, there is however an 
unsaid need for the LSPR Scanning reader. As depicted in Figure 44, this device is 
neither portable nor affordable, for it to be deployed in resource-limited settings.  
 
Figure 44: Varioskan LSPR reader, costing USD 42,000/- 
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In order to overcome this barrier, we have developed and designed a portable version of 
the same Varioskan Scanning mode reader with a simple optical set up.  
 
Figure 45: The Photometric scanning mode, operating physics. 
The proposed system has the three following basic components: Light source, Chip 
analyzer, Spectrometer. 
  
Figure 46: Components of a Portable version of LSPR b: High resolution spectrometer . 
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Figure 47: Components of the Spectrometer 
 
The description of each component shown in Figure 40 has been elaborated below in 
TaBle A1. 
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Table A1: Description of sub-components of the Spectrometer 
 
We used the Portable LSPR device to take measurements for the chips. We used a chip 
that had been incubated with Gold NP. Initially our results had a very large deviation 
from the expected absorbance spectrum for Au NP, due to a calibration problem. The 
original calibration had a dark region in the light source, indicating that the source light 
was not properly adjusted. This could have been the reason for the large deviation in the 
results. We recalibrated the device to adjust the light source and got relatively better 
results, that were closer to the 550 nm peak of Au NP. We have now set up  the platform 
inside the Plastic case in order to make measurements with liquid samples, in horizontal 
position. We have also started a fresh surface chemistry for using the portable LSPR 
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device in the horizontal position, for making measurements with liquid samples. The 
calibration of the device is depicted below: 
  
Figure 48: Fiber Optic Cable for calibrating the intensity of the light beam 
 
Each time we calibrate we measure the distance to the actual chip, so that there is 
reliability when we repeat the calibration for a different configuration. This experiment 
had 8.2 inches between light source and screen as shown below. 
After calibrating the device, we did a verification step, by comparing experimental data 
with theoretical formulation of absorption. The below formula can be used to compute 
the expected absorption in a sample.  
 
                
 
 
 
Table A2: Validation of device calibration by using the absorption formula 
 
        Aexperimental 
0.0048 0.005 
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In order to use the Portable LSPR device, we also need to select an appropriate substrate 
for the chips, that can be used for making the measurements [49]. The following brands 
with non-Gamma radiation sterilized plastics were tested for their absorption spectrum: 
Falcon, Costa, BD Falcon, Med supply. The results obtained are plotted below. 
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Figure 49 : Absorption spectra for each type of substrate. 
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Plot obtained from Portable LSPR device with BD Falcon substrate and Au NP   
(MATLAB Plot) and  a sample Plot from Ocean Optics Software of Portable LSPR are 
displayed below in Figure 42 and Figure 43. The MATLAB program using to find and 
plot the peak are shown in Appendix A. 
 
Figure 54: Absorption plots after MATLAB smoothing. 
 
 
Figure 51: Ocean Optics plot pre-processing with MATLAB 
The whole set-up was mounted inside the plastic container to tilt the chip-slot to 
horizontal position. 
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Figure 52: Internal view of the assembled portable LSPR 
 
We have also changed the design of the chip, in order to obtain multiple data points 
per channel. The new design is also adjusted to the size of the collimated beam of 
light from the Source Lamp in the Portable LSPR device. 
 
 
Figure 53: Old chip design for Portable LSPR and the new Chip design 
 
The chip was constructed by fixing the glass slide to PMMA and DSA layer cut with 
a laser cutter machine. 
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We prepared chips for testing the Portable LSPR device. We have completed the 
following Surface Chemistry. 
1. 150μL of 0.05mg/ml PLL in PBS  Incubation at 4° overnight  
 
2. 150μL of AuNP  Incubation at 4° overnight 
 
3. 150μL of 1mM MUA in PBS  Incubation at 4° for 3 hours. 
 
4. 150μL  of 191,7mg EDC+ 57,55mg NHS in MES Buffer (10ml) Incubation at 
4° overnight 
 
5. 150μL  of NeutrAvidin Incubation at 4° overnight 
 
 
The working of the portable LSPR device is based on the absorption spectra 
measurements. When light is passed though the PMMA-BD Falcon substrate chips, a 
fraction of the light is absorbed and the remaining components are transmitted. The 
spectrum peaks at wavelengths that got absorbed.  Beer Lamberts law states that:   
A = log (I0/I) 
where A is the absorbance, I is the intensity of transmitted light and I0 the intensity of 
incident light. An alternate version to the law is  
A= C*d* E 
where C is the molar concentration, d is the path length and E is the molar absorption 
coefficient.  However on using transparent PMMA chips, we observe that the data has too 
much of noise. The possible source for this noise is from scattering of light and 
diffraction at the chip edges. In order to test our hypothesis, we have designed the 
experiment with Black PMMA chips that can prevent light scattering and multiple 
internal diffraction effect. 
The results we obtained can be summarized as below: 
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Figure 54: Comparison of different wavelength peaks (nm) of CD4 and Platelet cells 
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Conclusion 
o Since there are small deviation from the expected trend in wavelength shift, we 
should repeat the surface chemistry to double check the data points, so that we 
can eliminate the possibility of human error while taking the measurement. 
 
o There could be a possible mathematical relationship between the amount of 
captured cells and the amount of peak shift 
 
o If we can determine this trend, then this platform can be multiplexed for detection 
many different types of pathogen based on the same principle 
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CONCLUSION 
In this report we have discussed various developments in the field of MEMS and 
nanotechnology addressing global healthcare challenges like early stage detection of 
infectious diseases by bringing the needed primary intervention at the point-of-care, i.e. 
closer to the patient, in resource constrained settings. In Chapter 1 we have briefly 
reviewed the work done by U. Demirci and Ali K. et al. [1] that covers a broad areas in 
lab-on-chip based technologies that integrates with CCD, or mobile phones and optical 
microscopes for pathogen detection. In Chapter 2 we have examined the detailed physics 
involved in the principle of Localized Surface Plasmon Resonance, a technique that relies 
on the change in wavelength shift and extinction intensity coefficient for the detection of 
pathogen and characterization of different types of viruses. The important advantage of 
LSPR based microfluidic detection platform is the label free nature of detection., which is 
not achievable through conventional gold standard techniques like ELISA. In Chapter 3 
we have seen how E. coli can be detected using lab-on-chip and have seen the associated 
surface chemistry that can be used to capture the bacteria from various sources like whole 
milk, phosphate buffer saline, human blood, or from spinach. Life threatening conditions 
like sepsis that arise due to E. coli infection has serious side effects like organ failure, 
increased blood lactose content, etc. are important factors for consideration to develop 
better and more affordable POC technologies that can be deployed in developing 
countries. In Chapter 4 we have presented an extensive report of the work done at the 
BAMM labs towards a nanoplasmonic platform that can detect viruses using a 
microfluidic platform. We demonstrate the ability to detect and quantify subtype A, B, C, 
D, E, G and panel of HIV with a specificity of under 100 copies/mL using both whole 
blood sample and HIV-patient blood sample discarded from clinics and this was 
compared against the gold standard using Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR). This microfluidic device has a total evaluation time for the assays of 
about 70 minutes, where 60 minutes is needed for capture and 10 minutes for data 
acquisition and processing. This LOC platform eliminates the need for any sample 
preparation before processing. This platform is highly multiplexable as the same surface 
chemistry can be adapted to capture and detect several other pathogens like dengue virus, 
E. coli, M. tuberculosis, etc. We also perform surface characterization using Atomic 
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Force Microscopy when the surface has polystyrene, Poly-L-Lysine, and Gold 
nanoparticle (AuNP). In the below diagram we illustrate the overall surface chemistry of 
the LSPR plates for detecting HIV subtypes. In chapter 6 we discuss the possibility to 
make the LSPR portable. We present the firsts steps toward this new challenge project 
that is still in progress.   
In conclusion, the breadth of this report shows the promise in continuing research on 
point-of-care devices that can address one of the most pressing challenges in global 
healthcare of bringing the patient closer to the technology for disease detection and also 
to make such novel technologies affordable. Potential extension of the work presented 
here includes, early stage cancer detection by sensing cancer biomarkers, CTC’s or other 
suitable indicators like siRNA. 
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APPENDIX A 
Matlab program to find the wavelength peak. 
clear all; 
close all; 
clc; 
filenamesuffix = '.txt'; 
TotalNumberofSamples = 16; 
DataForEachSample = 3; 
Datasuffixforsamples = ['a' 'b' 'c']; 
LowPassParameter = 100; 
ConsideredPartStart =475; 
ConsideredPartEnd = 650; 
  
  
  
filenameDirectory = '122113LSPRAfterGold\'; 
  
CalculationForPeakFinder 
  
DataAfterGold = [FreqAxis TempDataSet]; 
SmoothedDataAfterGold = [FreqAxis SmoothedTempData]; 
WavelenghtMaxPeakIndexAfterGold=WavelenghtMaxPeakIndex; 
DataAfterGoldPart = [FreqAxisPart TempDataSetPart(RLPP:end-RLPP,:)]; 
SmoothedDataAfterGoldPart = [FreqAxisPart SmoothedTempDataPart]; 
WavelenghtMaxPeakIndexPartAfterGold=WavelenghtMaxPeakIndexPart; 
  
filenameDirectory = '122113LSPRafterMUA\'; 
  
CalculationForPeakFinder 
  
  
DataAfterMUA = [FreqAxis TempDataSet]; 
SmoothedDataAfterMUA = [FreqAxis SmoothedTempData]; 
WavelenghtMaxPeakIndexAfterMUA=WavelenghtMaxPeakIndex; 
DataAfterMUAPart = [FreqAxisPart TempDataSetPart(RLPP:end-RLPP,:)]; 
SmoothedDataAfterMUAPart = [FreqAxisPart SmoothedTempDataPart]; 
WavelenghtMaxPeakIndexPartAfterMUA=WavelenghtMaxPeakIndexPart; 
  
  
  
  
filenameDirectory = '122113LSPRafterEDCNHS\'; 
  
CalculationForPeakFinder 
  
  
DataAfterEDCNHS = [FreqAxis TempDataSet]; 
SmoothedDataAfterEDCNHS = [FreqAxis SmoothedTempData]; 
WavelenghtMaxPeakIndexAfterEDCNHS=WavelenghtMaxPeakIndex; 
DataAfterEDCNHSPart = [FreqAxisPart TempDataSetPart(RLPP:end-RLPP,:)]; 
SmoothedDataAfterEDCNHSPart = [FreqAxisPart SmoothedTempDataPart]; 
WavelenghtMaxPeakIndexPartAfterEDCNHS=WavelenghtMaxPeakIndexPart; 
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filenameDirectory = '122113LSPRafterNA\'; 
  
CalculationForPeakFinder 
  
  
DataAfterNA = [FreqAxis TempDataSet]; 
SmoothedDataAfterNA = [FreqAxis SmoothedTempData]; 
WavelenghtMaxPeakIndexAfterNA=WavelenghtMaxPeakIndex; 
DataAfterNASPart = [FreqAxisPart TempDataSetPart(RLPP:end-RLPP,:)]; 
SmoothedDataAfterNAPart = [FreqAxisPart SmoothedTempDataPart]; 
WavelenghtMaxPeakIndexPartAfterNA=WavelenghtMaxPeakIndexPart; 
  
  
ShiftValues=[WavelenghtMaxPeakIndexAfterGold 
WavelenghtMaxPeakIndexAfterMUA WavelenghtMaxPeakIndexAfterNA... 
    WavelenghtMaxPeakIndexPartAfterGold 
WavelenghtMaxPeakIndexPartAfterMUA WavelenghtMaxPeakIndexPartAfterNA] 
ShiftAmount=[WavelenghtMaxPeakIndexAfterGold-
WavelenghtMaxPeakIndexAfterMUA ... 
    WavelenghtMaxPeakIndexPartAfterGold-
WavelenghtMaxPeakIndexPartAfterMUA ... 
    WavelenghtMaxPeakIndexPartAfterGold-
WavelenghtMaxPeakIndexPartAfterNA] 
  
MeanShiftValuesGraph=mean([ShiftValues(7:end,4) ShiftValues(7:end,5) 
ShiftValues(7:end,6)]) 
StdShiftValuesGraph=std([ShiftValues(7:end,4) ShiftValues(7:end,5) 
ShiftValues(7:end,6)])  
  
MeanShiftAmountGraph=mean(ShiftAmount(7:end,2)) 
StdShiftAmountGraph=std(ShiftAmount(7:end,2)) 
  
MeanShiftValuesGraph=mean([ShiftValues(7:end,3) ShiftValues(7:end,4)]) 
StdShiftValuesGraph=std([ShiftValues(7:end,3) ShiftValues(7:end,4)]) 
  
MeanShiftAmountGraph=mean(ShiftAmount(7:end,2)) 
StdShiftAmountGraph=std(ShiftAmount(7:end,2)) 
  
figure; 
bar(MeanShiftValuesGraph,0.1); 
hold on 
errorbar(MeanShiftValuesGraph,StdShiftValuesGraph,'r.') 
grid minor 
xlabel('Wavelength measurements after given step'); 
ylabel('Wavelength'); 
set(gca,'XTickLabel',{ 'Gold','MUA'}); 
  
ShiftValues=[WavelenghtMaxPeakIndexPartAfterGold... 
    WavelenghtMaxPeakIndexPartAfterMUA... 
    WavelenghtMaxPeakIndexPartAfterEDCNHS... 
    WavelenghtMaxPeakIndexPartAfterNA] 
ShiftAmount=[WavelenghtMaxPeakIndexPartAfterGold-
WavelenghtMaxPeakIndexPartAfterMUA ... 
    WavelenghtMaxPeakIndexPartAfterMUA-
WavelenghtMaxPeakIndexPartAfterEDCNHS ... 
    WavelenghtMaxPeakIndexPartAfterEDCNHS-
WavelenghtMaxPeakIndexPartAfterNA] 
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MeanShiftValuesGraph=mean(ShiftValues(7:end,:)) 
StdShiftValuesGraph=std(ShiftValues(7:end,:)) 
  
MeanShiftAmountGraph=mean(ShiftAmount(7:end,:)) 
StdShiftAmountGraph=std(ShiftAmount(7:end,:)) 
  
figure; 
bar(MeanShiftValuesGraph,0.1); 
hold on 
errorbar(MeanShiftValuesGraph,StdShiftValuesGraph,'r.') 
grid minor 
xlabel('Wavelength measurements after given step'); 
ylabel('Wavelength'); 
set(gca,'XTickLabel',{ 'Gold','MUA', 'EDC NHS', 'NA'}); 
  
ShiftValues=[WavelenghtMaxPeakIndexPartAfterGold... 
    WavelenghtMaxPeakIndexPartAfterMUA... 
    WavelenghtMaxPeakIndexPartAfterEDCNHS... 
    WavelenghtMaxPeakIndexPartAfterNA] 
ShiftAmount=[WavelenghtMaxPeakIndexPartAfterGold-
WavelenghtMaxPeakIndexPartAfterMUA ... 
    WavelenghtMaxPeakIndexPartAfterMUA-
WavelenghtMaxPeakIndexPartAfterEDCNHS ... 
    WavelenghtMaxPeakIndexPartAfterEDCNHS-
WavelenghtMaxPeakIndexPartAfterNA] 
  
MeanShiftValuesGraph=mean(ShiftValues(7:end,:)) 
StdShiftValuesGraph=std(ShiftValues(7:end,:)) 
  
MeanShiftAmountGraph=mean(ShiftAmount(7:end,:)) 
StdShiftAmountGraph=std(ShiftAmount(7:end,:)) 
  
figure; 
bar(MeanShiftValuesGraph,0.1); 
hold on 
errorbar(MeanShiftValuesGraph,StdShiftValuesGraph,'r.') 
grid minor 
xlabel('Wavelength measurements after given step'); 
ylabel('Wavelength'); 
set(gca,'XTickLabel',{ 'Gold','MUA', 'EDC NHS', 'NA'}); 
  
  
% close all; 
%  
% for i=1:TotalNumberofSamples 
%         figure; 
%         plot(FreqAxisPart, SmoothedDataAfterNAPart(:,(i-
1)*DataForEachSample+1)); 
%         hold on 
%         plot(FreqAxisPart, SmoothedDataAfterNAPart(:,(i-
1)*DataForEachSample+2),'r'); 
%         plot(FreqAxisPart, SmoothedDataAfterNAPart(:,(i-
1)*DataForEachSample+3),'g'); 
%         hold off 
%  
% end 
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%  
% DataAfterNA = [FreqAxis TempDataSet]; 
% SmoothedDataAfterNA = [FreqAxis SmoothedTempData]; 
% WavelenghtMaxPeakIndexAfterNA=WavelenghtMaxPeakIndex; 
% DataAfterNASPart = [FreqAxisPart TempDataSetPart(RLPP:end-RLPP,:)]; 
% SmoothedDataAfterNAPart = [FreqAxisPart SmoothedTempDataPart]; 
% WavelenghtMaxPeakIndexPartAfterNA=WavelenghtMaxPeakIndexPart; 
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APPENDIX A 
Artificial Saliva Recipe (can be stored for 1-2 weeks) 
Reference: “Galvanic currents between dental alloys in vitro” K ARVIDSON  et al. (1985) 
Artificial saliva has the following composition: 0.1 L each of 25 mM K2PO4, 24 Mm 
Na2HPO4,150 mM KHCO3, 1.5 Mm MgCl2. 0.006 L of 25 mM citric acid, and 0.1 L of 15 mM 
CaCl2 will be added to this solution.  
Salt MW (g/mol)  Molarity 
(mM=mmol/L) 
Volume (L) Weight (mg)  
K2HPO4 174.2 25 0.1 435.5 
 
Na2HPO4 141.96 24 0.1 340.704 
 
KHCO3 100.115 150 0.1 1501.725 
 
NaCl 58.443 100 0.1 584.43 
 
MgCl2 203.31 1.5 0.1 30.4965 
 
Citric acid 192.124 25 0.006 28.8186 
 
CaCl2 147.014 5 0.1 73.507 
 
 
To achieve a pH of 6.7 either add NaOH or HCl to the solution and adjust volume to 1L.  
 
 Proteins can be added to this solution.  
40 mg/L Albumin (Bovine serum albumin) and 850 mg/ml mucin (bovine submaxillary 
mucin)  
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Reference for proteins:   
1. Rheological aspects of mucin-containing solutions and saliva substitutes (1992) 
2. Influence of saliva substitute films on Streptoccous mutans (2008) 
 
 
 
